CN210683759U - Kit for drug sensitivity detection of pancreatic cancer - Google Patents
Kit for drug sensitivity detection of pancreatic cancer Download PDFInfo
- Publication number
- CN210683759U CN210683759U CN201921513697.7U CN201921513697U CN210683759U CN 210683759 U CN210683759 U CN 210683759U CN 201921513697 U CN201921513697 U CN 201921513697U CN 210683759 U CN210683759 U CN 210683759U
- Authority
- CN
- China
- Prior art keywords
- reagent
- reagent bottle
- kit
- bottle fixing
- box
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
A kit for drug sensitivity detection of pancreatic cancer comprises a kit body and a kit box, wherein the kit box is packaged in the kit body; the kit comprises fixed box of reagent bottle and magazine, the enzyme mark board has been inserted to the magazine, the reagent bottle fixed plate has been placed in the fixed box of reagent bottle, be fixed with expanding spring between the bottom of fixed box of reagent bottle fixed plate and reagent bottle, it has 6 fixed recesses of first reagent bottle and 4 fixed recesses of second reagent bottle to open on the reagent bottle fixed plate, place 6 drug sensitive reagent bottles and splendid attire methotrexate reagent respectively in the fixed recess of first reagent bottle, 5-uracil reagent, the mould reagent of splitting, the adriamycin reagent, epirubicin reagent and carboplatin reagent, the fixed recess of second reagent bottle is equipped with 4, the quantity of functional reagent bottle is 4 and splendid attire methyl azoate respectively, II type collagenase, RPMI-1640 culture solution and dimethyl sulfoxide solution. The kit is specially used for drug sensitivity detection tests of pancreatic cancer, prevents the problem of cross use of reagents and medicaments, and facilitates reagent and medicament management.
Description
Technical Field
The utility model relates to a quick detection technical field of tumour medicine, concretely relates to kit for quick detection of pancreatic cancer medicine.
Background
Treatment of pancreatic cancer remains a challenging topic in the surgical field, with difficult early diagnosis, low surgical resection rate, and high postoperative recurrence rate. Chemotherapy remains important in the combination treatment of pancreatic cancer. However, the chemotherapy effect of the pancreatic cancer is still not satisfactory at present, and the response rate is low no matter the chemotherapy is carried out singly or in combination. In order to screen and obtain chemotherapeutic drugs with good treatment effects, researchers need to perform multiple groups of drug sensitivity detection tests on pancreatic cancer cells. Due to the lack of a special pancreatic cancer drug sensitivity detection kit, the existing pancreatic cancer drug sensitivity detection test needs to purchase different reagents and medicaments produced by multiple families, and the reagents can be used for cell drug sensitivity detection of different tumors, so that the phenomenon of cross use often occurs, the management of the reagents of the kit is disordered, and the efficiency of the drug sensitivity detection test is reduced; because the reagent bottle is placed in the box body at a deeper position, the reagent bottle is very inconvenient to take and place.
SUMMERY OF THE UTILITY MODEL
In order to solve the problems, the utility model designs a reagent kit for drug sensitivity detection of pancreatic cancer, which is specially used for drug sensitivity detection test of pancreatic cancer, prevents the problem of cross use of reagents and medicaments, and facilitates the management of the reagents and the medicaments; simultaneously this kit from reset structure of bounceing can make things convenient for getting of reagent bottle and medicament bottle to use and place, has guaranteed that the fixed more stable groove depth of reagent bottle fixed slot greatly reduces in order to conveniently to take out reagent bottle and medicament bottle when the reagent bottle has been guaranteed.
In order to realize the technical purpose, reach above-mentioned technological effect, the utility model discloses a realize through following technical scheme:
a kit for drug sensitivity detection of pancreatic cancer is characterized by comprising a kit body and a kit box, wherein the kit box is packaged in the kit body; the kit is an integrated structure consisting of a reagent bottle fixing box and a cassette, the cassette is arranged on one side of the kit, a socket is arranged on the cassette, an enzyme label plate is inserted in the cassette, a reagent bottle fixing plate is arranged in the reagent bottle fixing box, a telescopic spring is fixed between the reagent bottle fixing plate and the bottom of the reagent bottle fixing box and arranged between the reagent bottle fixing box and the reagent bottle fixing plate, a first reagent bottle fixing groove and a second reagent bottle fixing groove are formed in the reagent bottle fixing plate, elastic clamping sheets are arranged in the first reagent bottle fixing groove and the second reagent bottle fixing groove, a drug sensitive reagent bottle is arranged in the first reagent bottle fixing groove, and a functional reagent bottle is arranged in the second reagent bottle fixing groove;
the number of the first reagent bottle fixing grooves is 6, the number of the drug sensitive reagent bottles is 6, the drug sensitive reagent bottles are respectively used for containing a methotrexate reagent, a 5-uracil reagent, a mitomycin reagent, an adriamycin reagent, an epirubicin reagent and a carboplatin reagent, the number of the second reagent bottle fixing grooves is 4, and the functional reagent bottles are 4 and respectively used for containing methyl azozolium, II-type collagenase, RPMI-1640 culture solution and dimethyl sulfoxide solution.
Preferably, the front panel of the reagent bottle fixing box is provided with a lower lock catch, the box cover of the reagent bottle fixing box is provided with an upper lock catch, and the box cover is hinged with the rear panel of the reagent bottle fixing box through a hinge and locked on the front panel through the upper lock catch.
Preferably, the elisa plate is a 96-hole plate, the box body is formed by printing paper materials, and the sleeve box is made of engineering plastics.
The utility model has the advantages that: the kit is specially used for drug sensitivity detection tests of pancreatic cancer, prevents the problem of cross use of reagents and medicaments, and facilitates reagent and medicament management; simultaneously this kit from reset structure of bounceing can make things convenient for getting of reagent bottle and medicament bottle to use and place, has guaranteed that the fixed more stable groove depth of reagent bottle fixed slot greatly reduces in order to conveniently to take out reagent bottle and medicament bottle when the reagent bottle has been guaranteed.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art that other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 is a schematic diagram of the assembly of a kit for drug-sensitive detection of pancreatic cancer;
FIG. 2 is a schematic structural view of the reagent bottle fixing cassette;
fig. 3 is a schematic structural view of the reagent bottle fixing cassette without the reagent bottle and the medicine bottle.
In the drawings, the components represented by the respective reference numerals are listed below:
1-box body, 2-box sleeve, 3-drug sensitive reagent bottle, 4-functional reagent bottle, 5-enzyme label plate, 21-reagent bottle fixing box, 22-cassette, 23-reagent bottle fixing plate, 24-expansion spring, 25-second reagent bottle fixing groove, 26-first reagent bottle fixing groove, 27-elastic clamping sheet, 211-box cover, 212-upper lock catch, 213-lower lock catch and 221-socket.
Detailed Description
The technical solutions in the embodiments of the present invention will be described clearly and completely with reference to the accompanying drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by a person of ordinary skill in the art without creative efforts belong to the protection scope of the present invention.
Referring to fig. 1-3, a kit for drug-sensitive detection of pancreatic cancer comprises a case body 1 and a kit 2, wherein the kit 2 is packaged in the case body 1; the cover box 2 is the integral type structure that fixed box 21 of reagent bottle and magazine 22 constitute, magazine 22 sets up in one side of cover box 21, it has socket 221 to open on magazine 22, the enzyme linked plate has been inserted in the magazine, the reagent bottle fixed plate has been placed in the fixed box of reagent bottle, be fixed with expanding spring 24 between the bottom of fixed box 21 of reagent bottle fixed plate 23 and reagent bottle, expanding spring 24 sets up between fixed box 21 of reagent bottle and reagent bottle fixed plate 23, it has first reagent bottle fixed recess 26 and second reagent bottle fixed recess 25 to open on the reagent bottle fixed plate 23, be equipped with curved elasticity holding piece 27 in first reagent bottle fixed recess 26 and the second reagent bottle fixed recess 25, elasticity holding piece 27 adopts stainless steel piece to make. The first reagent bottle fixing groove 26 is internally provided with a drug sensitive reagent bottle 3, and the second reagent bottle fixing groove 25 is internally provided with a functional reagent bottle 4;
the number of the first reagent bottle fixing grooves 26 is 6, the number of the drug sensitive reagent bottles 3 is 6, the drug sensitive reagent bottles are respectively used for containing methotrexate reagent, 5-uracil reagent, mitomycin reagent, adriamycin reagent, epirubicin reagent and carboplatin reagent, the number of the second reagent bottle fixing grooves 25 is 4, the number of the functional reagent bottles 4 is 4, and the functional reagent bottles are respectively used for containing methyl azozolium, II-type collagenase, RPMI-1640 culture solution and dimethyl sulfoxide solution.
The front panel of the reagent bottle fixing box 21 is provided with a lower lock catch 213, the box cover 211 of the reagent bottle fixing box 21 is provided with an upper lock catch 212, and the box cover 211 is hinged with the rear panel of the reagent bottle fixing box 21 through a hinge and locked on the front panel through the upper lock catch 212.
The methotrexate reagent in this example was purchased from Shanghai Hualian pharmaceutical factory, the 5-uracil reagent was purchased from Shanghai general pharmaceutical factory, the mitomycin reagent was purchased from Kyowa, the doxorubicin reagent was purchased from Nippon Mingming pharmaceutical company, the epidoxorubicin reagent was purchased from Zhejiang Haizi pharmaceutical factory, and the carboplatin reagent was purchased from Zilu pharmaceutical factory, China.
One specific application of the device is as follows: the kit 2 is taken out of the kit body 1, the box cover 211 is opened, the reagent bottle fixing plate 23 moves upwards under the reset action of the extension spring 24, the drug sensitive reagent bottle 3 and the functional reagent bottle 4 fixed on the reagent bottle fixing plate 23 extend out of the kit, and the drug sensitive reagent bottle 3 and the functional reagent bottle 4 are conveniently taken out of the reagent bottle fixing plate 23 at the moment.
The specific test operation of the pancreatic cancer drug sensitivity detection kit is as follows:
(1) taking a tissue sample of human pancreatic cancer (about 1cm in area) removed by operation2) Removing fat, fibrous tissues, blood clots and necrotic tissues on a super clean bench, cleaning by using Hanks liquid, placing the cleaned tissue in a 75mm multiplied by 15mm dish, shearing into fragments with the diameter of 1-3 mm, adding 0.1% type II collagenase for digestion, preparing single pancreatic cancer cell suspension, counting living cells by using trypan blue, and requiring the number of the living cells to be more than 90%.
(2) The obtained cell strain is cultured in RPMI-1640 culture medium containing 10% fetal calf serum, and when the cells grow vigorously, 0.1% type II collagenase is added for digestion, and the cell concentration is 5 × 104mL, cells were seeded on an ELISA plate 5 (200 uL/well) and cultured for 12 hours;
(3) adding sterile physiological saline into a reagent in a drug sensitive reagent bottle 3, then carrying out compatibility to obtain a single or mixed chemotherapeutic drug, replacing the chemotherapeutic drug by a PBS buffer solution in a chemotherapeutic drug control group, adding the compatible chemotherapeutic drug and the PBS buffer solution into an inoculated enzyme-labeled plate hole, replacing 10% fetal bovine serum RPMI-1640 fresh culture solution in culture for 1, 8 and 24 hours respectively, continuing to culture for 72 hours, replacing the fresh culture solution, adding methyl azozolium (MTT) in a functional reagent bottle, continuing to culture for 4 hours, discarding supernatant, adding 100uL of dimethyl sulfoxide (DMSO) solution into each hole, dissolving the formazan compound completely at room temperature, carrying out OD determination by using an enzyme-labeled analyzer, and determining lambda as 579 nm.
(4) And (3) judging the standard, wherein the relative inhibition rate is (the OD value of a control group-the OD value of a medicine adding group) multiplied by 100 percent/the OD value of the control group, the relative inhibition rate is more than or equal to 50 percent and is sensitive, the relative inhibition rate is 30 to 50 percent and is insensitive, and the relative inhibition rate is less than 30 percent.
(5) And (3) adopting a random block and analysis method, and adopting SAS data statistical software to process to obtain a result and then analyze the result so as to finish the pancreatic cancer drug sensitivity detection test.
In the description herein, references to the description of "one embodiment," "an example," "a specific example," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the present invention disclosed above are intended only to help illustrate the present invention. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical applications, to thereby enable others skilled in the art to best understand the invention for and utilize the invention. The present invention is limited only by the claims and their full scope and equivalents.
Claims (3)
1. A kit for drug sensitivity detection of pancreatic cancer is characterized by comprising a kit body and a kit box, wherein the kit box is packaged in the kit body; the kit is an integrated structure consisting of a reagent bottle fixing box and a cassette, the cassette is arranged on one side of the kit, a socket is arranged on the cassette, an enzyme label plate is inserted in the cassette, a reagent bottle fixing plate is arranged in the reagent bottle fixing box, a telescopic spring is fixed between the reagent bottle fixing plate and the bottom of the reagent bottle fixing box and arranged between the reagent bottle fixing box and the reagent bottle fixing plate, a first reagent bottle fixing groove and a second reagent bottle fixing groove are formed in the reagent bottle fixing plate, elastic clamping sheets are arranged in the first reagent bottle fixing groove and the second reagent bottle fixing groove, a drug sensitive reagent bottle is arranged in the first reagent bottle fixing groove, and a functional reagent bottle is arranged in the second reagent bottle fixing groove;
the number of the first reagent bottle fixing grooves is 6, the number of the drug sensitive reagent bottles is 6, the drug sensitive reagent bottles are respectively used for containing a methotrexate reagent, a 5-uracil reagent, a mitomycin reagent, an adriamycin reagent, an epirubicin reagent and a carboplatin reagent, the number of the second reagent bottle fixing grooves is 4, and the functional reagent bottles are 4 and respectively used for containing methyl azozolium, II-type collagenase, RPMI-1640 culture solution and dimethyl sulfoxide solution.
2. The kit for drug sensitivity detection of pancreatic cancer according to claim 1, wherein the front panel of the reagent bottle fixing box is provided with a lower lock catch, the box cover of the reagent bottle fixing box is provided with an upper lock catch, and the box cover is hinged with the rear panel of the reagent bottle fixing box through a hinge and locked on the front panel through the upper lock catch.
3. The kit for drug-sensitive detection of pancreatic cancer according to claim 1, wherein the elisa plate is a 96-well plate, the kit body is printed with paper material, and the kit is made of engineering plastic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921513697.7U CN210683759U (en) | 2019-09-11 | 2019-09-11 | Kit for drug sensitivity detection of pancreatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921513697.7U CN210683759U (en) | 2019-09-11 | 2019-09-11 | Kit for drug sensitivity detection of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN210683759U true CN210683759U (en) | 2020-06-05 |
Family
ID=70893004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201921513697.7U Expired - Fee Related CN210683759U (en) | 2019-09-11 | 2019-09-11 | Kit for drug sensitivity detection of pancreatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN210683759U (en) |
-
2019
- 2019-09-11 CN CN201921513697.7U patent/CN210683759U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100519527C (en) | Inhibitors of histone deacetylase | |
| CN101450934B (en) | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | |
| IE67639B1 (en) | Compound for the reversal of multidrug resistance of cancer cells against cytotoxic drugs | |
| WO2002040717A3 (en) | In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals | |
| TW409149B (en) | Process for detecting microorganism using insect hemolymph | |
| CN210683759U (en) | Kit for drug sensitivity detection of pancreatic cancer | |
| BRPI0407907A (en) | aryl cycloalkyl substituted alkaline acid derivatives, processes for preparing them and using them as medicines | |
| McLachlan et al. | Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. | |
| Yalowich | Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro | |
| Rogers et al. | Role of the sigma receptor in the inhibition of [3H]-noradrenaline uptake in brain synaptosomes and adrenal chromaffin cells. | |
| Tobey et al. | Differential effects of two chemotherapeutic agents, streptozotocin and chlorozotocin, on the mammalian cell cycle | |
| CN108267537A (en) | A kind of method of Cortex Phellodendri in discriminating shangqing pill | |
| CN114317442A (en) | Culture medium for establishing mammary gland organoid or/and breast cancer organoid, method and application | |
| Bondevik et al. | A mixed lymphocyte culture micro‐technique and its application in different family and unrelated combinations | |
| CN202063921U (en) | Full-automatic blood culture instrument | |
| CN206740749U (en) | A kind of dissolution test sample rack | |
| CN113876771B (en) | Small molecule drug targeting PABPC1 and application thereof in chronic myelogenous leukemia | |
| EP4245417A1 (en) | Device for detecting an analyte in a sample | |
| CN218531013U (en) | Heparin tube accomodates pipe support | |
| Josefsson et al. | Pharmacokinetics of a new, microencapsulated erythromycin base after repeated oral doses | |
| CN219447777U (en) | Urine sample temporary storage device capable of preventing bacteria from propagating | |
| CN107385020A (en) | Application of the leptin in people recombinates the detection of FGF21 protein actives | |
| CN102988066B (en) | Vacuum blood collection tube containing separation gel and application thereof | |
| Ogbadoyi et al. | Proteinuria in malaria patients in Minna, Nigeria | |
| CN100372537C (en) | Use of tyrosine kinase inhibitor to treat diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200605 Termination date: 20210911 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |